Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B. infantis Supplementation in Healthy Breastfed Infants
NCT02286999Phase 1Withdrawn
- Start
- Oct 2015
- Primary completion
- Jan 2018
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atopic dermatitis (AD) and food allergy comparing B. infantis with Placebo (2 arms). Primary endpoints: Pharmacologically effective dose (ED) of B. infantis at 6 weeks and Safety of Probiotic Supplementation at 2 years. Planned start Oct 2015; status: withdrawn.
02
Drugs
Bifidobacterium longum subsp. infantis
03
Conditions
atopic dermatitis (AD)food allergy
Beyond the preview
Go deeper on NCT02286999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02286999.